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prospective double-bllnd study, patients were randomized to placebo (P) or 
low-done (10 rag/pay) Niea in the fhet weed, after Mi and reexamined 2hem, 
~. 6 and 18 months later. Exclusions were clinical heart faifure, uncontrolled 
hypertension and angina pactoris. At baseline (mean 4- sd), age was 56 4- 
8 and 56 4- ¢ yearn, infarct size (biplane cinsanglugraphy) 16 =1= 14 and 12 
4.12% o~ I v radmnudlde LV ejection fraction (EF) 45 4.11 m~l 44 4.15°/=, 
end-dlssk,:, volume (gated SPEC") 155 4. 29 and 142 4. 26 ml, wedge 
pressure (Swan-Ganz c~t~',tsr) '~' -~ 4 and 12 4. 5 mmHg m P (n = 20) 
and Nlso (n = 15), rasl~ ~::t, ~, Progressive LV dilation ocouwed with Niso 
(ANOVA p ,, 0.521) but no', :;, ~'i i~(T, Jre;'p<0.05vs.6monthe;1"p<0.05 
vs. P). 
Thus, even eaw-ganeration vasodilating COB such as nisoldlpine may be 
conlreindiceted even at low dose in patients with mild LV dysfunction. 
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J ' -~- - '~ Effect o f  Amlodlpine on Tolerance Exercise 8nd 
Quality o f  Life In Mild-To-Moderate Heart Failure 
With Syatoli¢ Dysfunction 
James E. Udaissn, C. Andrew DeAbate, Nampam Vi]ay, Stovan Chryeanto 
Kdshan Goyle, !wing Loh, Joel SkJar. William Smith. Marvin A. Konstam and 
the Amiodipine Exercise Trial Group. Tufts.New England Med Ctr,, Boston, 
MA 
We assessed the effect and safety of adjuvant reatment with amiodiplse 
(Amlo) on exercise tolerance and quality of life (QOL) in 152 patients with 
mild-to-modereta heart failure (59% NYHA class 2, 39% class 3) and LV 
systolic dysfunction (mean LV EF 23%). 192 such 10is with stable baseline 
exercise times were randomized in a double blind placebo controlled trial to 
Amlo (lflreted to 10 mg per day) or to placebo for 12 weeks. In 59% of lots, 
ischemic heart disease was the etiology of heart failure, and 83% of 10ts were 
on ACE inh~itors. QOL was measured with questionnaires including Living 
with Heart Failure (LHF), Health Perception, Alertness, and # of days in bed. 
Results (means): 
Amlo Plaoabo p 
Base Final Change Base Final Change 
Exercise time (sac) 545 608 +63 558 619 +61 0.5 
6 rain walk (yards) 399 401 +2 372 395 +23 0.2 
LV EF (%) 23 27 +4 23 26 +3 0.3 
LHF so0m 67 70 +3 70 73 +3 0.9 
Health pe~plton 49 53 +4 51 52 +1 0.09 
# bed dsys 0.4 0.6 +0.2 0.7 0.4 -0.3 0.2 
Alertness 86 90 -t-4 85 86 +1 0.1 
There were no differences between groups in change in NYHA class or 
symptoms, and, in contrast o prior sk.,d]es with calcium channel blockers, no 
difference in the need for increasing background heart failure therapy. Side 
effects were similar in the two groups, save for a small excess of mild edema 
in the Amio group. These data suggest that the addition of 10 mg Amlo to 
standard therapy in mild-to-modarato heart failure results in no Important 
changes in exercise time over 12 weeks of therapy, and Is also safe and well 
tolerated. 
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~ Circadian Rhythm and Sudden Death In Heart 
Failure: Results From PRAISE 
Peter Carson, Milton Preesler, Alan Miller, Susan Andemon, Robert Belkin, 
David Fdd, Gerald Neubarg, Chflstophsr O'Connor, John Werthaimer, 
Milton Packer for the PRAISE Investigators. VA Medical Center, 
Washington DC; Georgetown University Medical Centers, Washington, DG 
Previous analyses have indicated a temporal relation of acute cardiovas- 
cular events, particularly In the early morning due to neurohormonal (NH) 
activation. We postulated that the chronic NH stimulation in heart failure 
(HF) would produce an uniform pattern of sudden death (SD) events. There 
were 185 SD in '=RAISE with approximating time of death for 152 pts. We 
analyzed for unik.~.nlty using a chl-sqeare statistic end 4 hour intervals, The 
results showed significant non-uniform!ly (p = 0.01) with a P.M. peak for the 
entire cohort. When analyzing by HF etiology, ischemlc (I) pts circadian SD 
distribution differed from nonischemic (NI) (p = 0.001, with I pts showing the 
P,M, peak while NI pts did not. 
By treatment, he distribution of events did not significantly differ. Conclu- 
SS m~Vln dl lgl l ;  n .  1111 l~n,!lldtmd~ p l t l l~ l  wk'1~, n = I~ II~lem~ luztll1111 ~,  n .  10B 
=' , , ,=-  - = - - ,  
¢~lmlmml  czm~m blznll C~Im Irllm~l~ 
ston: In PRAISE, HF pts showed a non-uniformity of SD events with late 
affamnon peak. The presence of this peak in iashemfo but not nonlschemlo 
patients raises the hypothesis that these SO events were in large part is- 
chemic. An early A.M. peak suggesting a nourohormonal effect was not seen. 
Amlodipine treatment did not significantly alter the dlstn'bution of events. 
9:15 
~ Dissociation Between the Inotreplc and Systemic 
Effects o f  the Calcium Promoter BAY y 5959 In 
Patlents Wilh Heart Failure 
Michel F. Rousseau, Plee'e E. Maseart, Christian van Eyll, Jean Etienoe, 
Sylvle Ahn, Liviu Stoleru, Mariln Bomemann, Hubert Pouleur. Univars~ of 
Lnovain, Brussels, Belgium 
The effects of the calcium promoter BAY y 5959 (BAY) on LV function 
(angiogrephy + MiJlar) and systemic h ~ l c e  were studied in 20 
with severe heart failure (NYHA Ill-W, moan LVEF 17%, range 6-32%). 
Data were obtained before and after 20 rain infusion of BAY at 4 dose levels 
(1, 2, 3 and 4.5 p.g/kg/min; 5 pts per dose). Heart rate arKI LV end-diastolic 
pressure decreased at each dose level (average 85 to 75" bpm and 29.2 
to 24.9" mmHg) but the effects on the isovolumic indices of inotrepfo stats, 
cardiac index ((31) and systemic vascular resistance (SVR) vailed mere with 
dose. 
Dose &CI &$VR ~dP/dt Max &(dP/dl)/DP40 
(t~g/l<g/min) (%) (%) (%) (%) 
1 -0:1:8 54-7 0-4-5 15=E4 = 
2 23±13 = -14:E9" 14-;-6" 19:1=14 
3 11 4-6" -7 =b 11 25-1-10" 44-1-17" 
4.5 8:E13 5:~13 56-*-10 °= 72:1:12 'o 
°p < 0.05 "p  < 0.001 mean ~ SEM 
Mean systolic stress was unchanged and LVEF improved (in absolute 
values) by 2.b~ro ", 4.4%*, 6.6%* and 12,8%" at the 1, 2, 3 and 4.5 doses, 
respectively. Relaxation rate was unaffected and QTc was prolonged but 
no prcerrhythmia was detected. Thus, in this study, the optimal response, 
combining bredysardia, reduced prelead and improved systemic perfusion is 
achieved around 2 p.g/kg/min, and BAY appears premising for intravenous 
use in severe pump failure. 
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_Dose and Circadian Dependent Autonomic 
HeapOnea tO Veaodllation With Amlodlplne In 
uongeat ive Heart Failure 
Philip F. Btnldey, Enrfco Nunziate, Patricia S. Hatton, Robert J. Cod),. The 
Ohio State University, Columbus, Ohio 
The influence of the calcium channel blocker amfodipine [Atoll on the auto- 
nomlc imbalance characteristic in congestive heart failure [CHF] Is currently 
unknown. We therefore assessed diurnal patfams of autonomic tone using 
spectral analysis Of heart rata variability [I-IRV] performed on each hour of 
Holler recordings obtained on 51 patients with CHF at baseline [Ba] and after 
3 months of treatmnnt ['rr] with either placebo [P] or 5 or 10 mg of Ami in ad- 
dition to standard therapy. The diurnal pattom of parasympatheticetiy [para] 
gevemed high frequency It-IF] HRV did not differ ~mong groups at baseline; 
however, 10 mg, but not 5 mg of Aml produced a algnificsntly [ANOVA p 
= 0.03] different diurnal pattern of HF HRV compared to P. This ditference 
resulted from an increase in HF HRV [heatS/min]~/Hzl] between 3 and 8 AM 
with 10 mg Aml [Ba: 2.83 x 10 -s 4. 0.48 x 10 --4 vs Tr: 3.46 x 10 -'q .4- 0.60 
x 10 "4] which significantly differed [ANOVA p = 0.02] from a decrease seen 
in P [Be: 3.21 x 10 -s 4- 0.43 x 10-4 vs Tr: 2.84 x 10 4 4- 0,38 x 10-4]. 
However, between 9 PM and 2 AM, 10 rog Aml decreased HF HRV [Ba: 3.08 
x 10 -s 4- 0.50 x 10-4 vs Tr: 2,54 x 10 "a 4- 0.43 x 10 "4] which s/gnifisantly 
differed [ANOVA p = 0.04] from an increase noted with P [IZA: 3.27 x 10 -s 4- 
0.37 x 10 -4 vs Tr: 3.60 x 10 -s 4- 0.39 x 10-4]. Differences from P were not 
seen at other times. Therefore, 1. Only 10 mg daily Ami significantly alters 
autonomic tone in CHF; 2. Ami assodafad changes in pare tone vary with 
time of day. The augmentation of parasympathetic tone between 3 and 8 AM 
may be protective at this time in which vulnerability to vantricular arrhythmias 
is typically increased. 
